Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY

Zai Lab Ltd

2022-FY EPS reported -$0.46 revenue$215,040,000

Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.
Net loss narrowed to $443.3M from $704.5M in 2021; cash position $1.0B as of Dec 31, 2022.
Expects commercial profitability in 2023 and overall corporate profitability by end of 2025.
Key pipeline milestones: BLA submission for efgartigimod in gMG, NDA for repotrectinib, and initiation of KarXT bridging study in China.
Appointed Michel Vounatsos to Board and Rafael Amado as President, Global Oncology R&D.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zai Lab Ltd reported the year ended December 31, 2022 results: revenue $215.0 million.

Period: the year ended December 31, 2022
Revenue: $215.0 million
Result: reported results

Exact text from the filing

ai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates – Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth – Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 – Company to host conference call and webcast on March 2, 2023, at 8:00 a.m.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-23-005822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.